Related Experiment Video
Updated: Apr 21, 2026
08:35
Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes
Published on: July 17, 2021
22.4K
Apolipoprotein E gene polymorphisms are associated with primary hyperuricemia in a Chinese population
Jie Wu1, Ling Qiu1, Xiu-zhi Guo1
1Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China.
Plos One
|October 31, 2014
Summary
The Apolipoprotein E (APOE) ε2 allele and APOE-ε2ε3 genotype are linked to higher serum uric acid levels. Individuals with the APOE-ε2 allele show an increased risk of developing hyperuricemia.
Area of Science:
- Genetics
- Human Health
- Biochemistry
Background:
- Primary hyperuricemia is a significant public health issue.
- It is associated with gout, metabolic syndrome, hypertension, and cardiovascular disease.
- Understanding genetic factors like Apolipoprotein E (APOE) polymorphisms is crucial for managing hyperuricemia.
Purpose of the Study:
- To investigate the genetic association between Apolipoprotein E (APOE) polymorphisms and hyperuricemia.
- To assess the risk of hyperuricemia in relation to specific APOE genotypes and alleles in a Chinese population.
Main Methods:
- A case-control study involving 770 subjects (356 hyperuricemic cases, 414 normouricemic controls) from China.
- Biochemical tests were performed on collected blood samples, including uric acid and lipid levels.
- Multi-ARMS PCR was used to determine APOE genotypes and analyze allele frequencies.
Main Results:
- The APOE-ε2ε3 genotype and APOE-ε2 allele were significantly more frequent in hyperuricemic cases compared to controls.
- This association was observed in both male subjects and across different ethnic groups (Han and Hui).
- Multivariate logistic regression confirmed that carriers of the APOE-ε2ε3 genotype and ε2 allele had a significantly higher risk of hyperuricemia (OR=2.194 and OR=2.099, respectively).
Conclusions:
- The APOE-ε2ε3 genotype and APOE-ε2 allele are significantly associated with elevated serum uric acid levels.
- Individuals carrying the APOE-ε2 allele have an increased risk of developing hyperuricemia.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
01:05Single Nucleotide Polymorphisms-SNPs
14.1K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.1K
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
182
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
182
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
152
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
152
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
303
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
303
01:29Pharmacogenomics: Identification of New Drug Targets
113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113